M T Groot

Summary

Affiliation: Erasmus University
Country: The Netherlands

Publications

  1. ncbi Costs of prostate cancer, metastatic to the bone, in the Netherlands
    M T Groot
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, Room L3 105, 3000 DR Rotterdam, The Netherlands
    Eur Urol 43:226-32. 2003
  2. ncbi [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ]
    M T Groot
    Erasmus Universiteit, Institute for Medical Technology Assessment, Postbus 1738, 3000 DR Rotterdam
    Ned Tijdschr Geneeskd 147:1460-5. 2003
  3. ncbi [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation]
    M T Groot
    Institute for Medical Technology Assessment, Erasmus Medisch Centrum, Postbus 1738, 3000 DR Rotterdam
    Ned Tijdschr Geneeskd 148:480-4. 2004
  4. ncbi Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia
    M van Agthoven
    Institute for Medical Technology Assessment, Department of Health Care Policy and Management, Erasmus University Rotterdam, The Netherlands
    Bone Marrow Transplant 30:243-51. 2002
  5. ncbi Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands
    M T Groot
    Erasmus Medical Centre, Institute for Medical Technology Assessment, Rotterdam, The Netherlands
    Eur J Haematol 74:194-202. 2005
  6. ncbi Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits
    C A Uyl-de Groot
    Department of Health Care Polity and Management, Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, The Netherlands
    Vaccine 23:2379-87. 2005

Collaborators

Detail Information

Publications6

  1. ncbi Costs of prostate cancer, metastatic to the bone, in the Netherlands
    M T Groot
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, Room L3 105, 3000 DR Rotterdam, The Netherlands
    Eur Urol 43:226-32. 2003
    ....
  2. ncbi [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ]
    M T Groot
    Erasmus Universiteit, Institute for Medical Technology Assessment, Postbus 1738, 3000 DR Rotterdam
    Ned Tijdschr Geneeskd 147:1460-5. 2003
    ..To determine the average cost-effectiveness ratio of treatment of patients with chronic myeloid leukaemia (CML): with first-line interferon alpha-2a (IFN) or with second-line imatinib following IFN failure...
  3. ncbi [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation]
    M T Groot
    Institute for Medical Technology Assessment, Erasmus Medisch Centrum, Postbus 1738, 3000 DR Rotterdam
    Ned Tijdschr Geneeskd 148:480-4. 2004
    ....
  4. ncbi Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia
    M van Agthoven
    Institute for Medical Technology Assessment, Department of Health Care Policy and Management, Erasmus University Rotterdam, The Netherlands
    Bone Marrow Transplant 30:243-51. 2002
    ..For patients who were alive after 2 years, cumulative expenses were calculated to be Euro 103,509 (BMT), Euro 173,587 (MUD), and Euro 105,906 (PBSCT)...
  5. ncbi Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands
    M T Groot
    Erasmus Medical Centre, Institute for Medical Technology Assessment, Rotterdam, The Netherlands
    Eur J Haematol 74:194-202. 2005
    ..88 QALYs. The ICER of 13 983 for younger and 17 933 for older patients per QALY gained should, seen in the light of disease severity, be considered acceptable by most policy makers in priority setting for budget allocation...
  6. ncbi Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits
    C A Uyl-de Groot
    Department of Health Care Polity and Management, Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, The Netherlands
    Vaccine 23:2379-87. 2005
    ....